Tracer library / [161Tb]Tb-BPAMD

Structure of BPAMD (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 66557879

[161Tb]Tb-BPAMD

Also written as [Tb-161]Tb-BPAMD

Radionuclide: Tb-161 t½ 9907.2 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

Bone metastases and bone lesions

What it is

Compound class: DOTA-conjugated bisphosphonate
Target / mechanism: Hydroxyapatite binding at sites of bone remodeling (bone-seeking bisphosphonate) PMID 41900797
Clinical application: Targeted radionuclide therapy of bone metastases PMID 41900797
Theranostic pair: [68Ga]Ga-BPAMD

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>98%	>97% at 48 h	BPAMD ABX	41900797 2026 Pharmaceutics A solution of 100 µg BPAMD in 0.5 mL acetate buffer (0.4 M, pH 4.5) was mixed with 74 MBq of 161TbCl3 and heated at 95 °C for 30 min in a sealed vial. - Both complexes achieved a radiochemical yield of greater than 98%.

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: ABX
Typical final purification: —

Need this precursor?We can point you to suppliers for [161Tb]Tb-BPAMD, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68.